Search Results - "Mai, Wenyuan"

Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients by Lou, Yinjun, Ma, Yafang, Sun, Jianai, Ye, Xiujin, Pan, Hanzhang, Wang, Yungui, Qian, Wenbin, Meng, Haitao, Mai, Wenyuan, He, JingSong, Tong, Hongyan, Jin, Jie

“…The aim of the study is to better understand the mechanism of relapse and acquired clinical resistance to arsenic trioxide (ATO) and/or all-trans retinoic acid…”
Get full text

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center by Zhu, Yanan, Zhang, Xiang, Wei, Juying, Yang, Chunmei, Tong, Hongyan, Mai, Wenyuan, Yang, Min, Qian, Jiejing, Mao, Liping, Meng, Haitao, Jin, Jie, Yu, Wenjuan

“…Abstract The combination of rituximab, lenalidomide, and Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib, followed by chemotherapy, has shown high efficacy…”
Get full text

The clinical impact of IKZF1 mutation in acute myeloid leukemia by Zhang, Xiang, Huang, Aijie, Liu, Lixia, Qin, Jiayue, Wang, Chengcheng, Yang, Min, Lou, Yinjun, Wang, Lei, Ni, Xiong, Hu, Xiaoxia, Tang, Gusheng, Zhang, Mengmeng, Cao, Shanbo, Mao, Liping, Qian, Jiejin, Xu, Weilai, Wei, Juying, Xu, Gaixiang, Meng, Haitao, Mai, Wenyuan, Yang, Chunmei, Zhu, Honghu, Tong, Hongyan, Yang, Jianmin, Yu, Wenjuan, Wang, Jianmin, Jin, Jie

“…Genetic heterogeneity poses a great challenge to the understanding and management of acute myeloid leukemia (AML). Knowledge of the IKZF1 mutation in AML…”
Get full text

Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia by Lou, Yinjun, Ma, Yafang, Li, Chenyin, Suo, Sansan, Tong, Hongyan, Qian, Wenbin, Mai, Wenyuan, Meng, Haitao, Yu, Wenjuan, Mao, Liping, Wei, Juyin, Xu, Weilei, Jin, Jie

“…A CALLG2008 protocol was developed by the Chinese Acute Lymphoblastic Leukemia Cooperative Group for adult acute lymphoblastic leukemia （ALL）. We…”
Get full text

Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China by Tong, Hongyan, Ren, Yanling, Qian, Wenbin, Xiao, Feng, Mai, Wenyuan, Meng, Haitao, Jin, Jie

“…We reviewed 173 patients with an initial diagnosis of peripheral T - cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement…”
Get full text

Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study by You, Liangshun, Liu, Yi, Mai, Wenyuan, Zhou, De, Xie, Wanzhuo, Mao, Liping, Zhou, Xinping, Tong, Hongyan, Jin, Jie, Meng, Haitao

“…7025 Background: While the understanding of AML has been improved over decades, the outcome of relapsed/refractory AML remains dismal. Venetoclax-based regimen…”
Get full text

Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study by You, Liangshun, Liu, Yi, Mai, Wenyuan, Xie, Wanzhuo, Zhou, De, Mao, Liping, Chen, Lili, Zhou, Xinping, Ma, Liya, Zheng, Xiaolong, Wei, Juying, Lou, Yinjun, Ye, Xingnong, Tong, Hongyan, Jin, Jie, Meng, Haitao

“…The outcome of relapsed/refractory (R/R) acute myeloid leukemia (AML) remains extremely poor. Venetoclax (VEN)-based regimens have shown promise in treating…”
Get full text

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: Interim Analysis of a Prospective, Multicenter, Phase 2 Trial by Suo, Shanshan, Yu, Wen-Juan, Lu, Ying, Qian, Jiejing, Mao, Liping, Wang, Jin, Shen, Lijing, Li, Bingzong, Wang, Huafeng, MAI, Wenyuan, Xie, Wanzhuo, Wang, Xiaomin, Zhao, Dan, Liu, Yuanfang, He, Chuan, Jin, Jie

“…Background: Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is identified as a subset of T-lineage ALL with a unique immunophenotype and genome…”
Get full text

Venetoclax Combined with Daunorubicin and Cytarabine (DAV) As Induction Therapy in De Novo Young Adult Acute Myeloid Leukemia by Wang, Huafeng, Mao, Liping, Xie, Wanzhuo, Tong, Hongyan, Yang, Min, Xu, Gaixiang, Ye, Xiujin, Lu, Ying, Wei, Juying, Mai, Wenyuan, Zhou, De, Jin, Jie, Zhu, Hong-Hu

“…▪ Background: Anthracycline and cytarabine (“3+7”) have been the standard induction therapy for acute myeloid leukemia (AML) for almost 4 decades. Only 60%-70%…”
Get full text

A Real World Study of Venetoclax Combined with Azacitidine in 64 Chinese Patients Newly Diagnosed Acute Myeloid Leukemia by Qian, Jiejing, Xu, Jieyu, Hong, Qing, Lou, Yinjun, Mao, Liping, Xu, Weilai, Yang, Min, Yu, Wenjuan, Meng, Haitao, Mai, Wenyuan, Ye, Xiujing, Zhu, Honghu, Jin, Jie

“…Background: Venetoclax combined with azacitidine has been demonstrated to have a favorable overall response rate and tolerable safety in acute myeloid leukemia…”
Get full text

Trimethoprim-sulfamethoxazole prevents interstitial pneumonitis in B-cell lymphoma patients receiving chemotherapy: a propensity score matching analysis by Liu, Chunxiao, Zhang, Xuewu, Zhu, Yanan, Wei, Juying, Ye, Xingnong, Yang, Chunmei, Tong, Hongyan, Mai, Wenyuan, Yang, Min, Qian, Jiejing, Mao, Liping, Meng, Haitao, Jin, Jie, Yu, Wenjuan

“…B-cell lymphoma is the most prevalent type of non-Hodgkin lymphoma, for which the standard treatment regimen includes rituximab combined with CHOP. However,…”
Get full text

Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial by Wang, Huafeng, Mao, Liping, Yang, Min, Qian, Pengxu, Lu, Huan, Tong, Hongyan, Xie, Wanzhuo, Zhou, De, Huang, Xin, Wang, Yungui, Xu, Gaixiang, Lu, Ying, Wei, Juying, Mai, Wenyuan, Ye, Xiujin, Meng, Haitao, Shen, Yaojia, Huang, Jian, Yu, Wenjuan, Sun, Jie, Sheng, Jianpeng, Yan, Xiaoyan, Jin, Jie, Zhu, Hong-Hu

“…Adults with acute myeloid leukaemia have unsatisfactory clinical outcomes and rates of complete remission. Venetoclax combined with azacytidine or low-dose…”
Get full text

How Induction Cycles before Remission Influence Long-Term Survival in Acute Myeloid Leukemia by Zhu, Feng, Chen, Nianci, Zhou, Yile, Zhang, Yi, Huang, Jian, Xie, Wanzhuo, Meng, Haitao, Yu, Wen-Juan, Mao, Liping, MAI, Wenyuan, Yang, Chunmei, Wei, Juying, Lou, Yinjun, Yang, Min, Qian, Jiejing, Xu, Gaixiang, Zhou, De, Ma, Liya, Ye, Xingnong, Ren, Yanling, Tong, Hongyan, Wang, Huafeng, Jin, Jie

“…Background ： Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by accumulation and expansion of immature myeloid cells in the…”
Get full text

Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia by Lou, Yinjun, Ma, Yafang, Sun, Jianai, Suo, Sansan, Tong, Hongyan, Qian, Wenbin, Mai, Wenyuan, Meng, Haitao, Jin, Jie

“…Early death is the main obstacle for the cure of patients with acute promyelocytic leukemia (APL). We have analyzed risk factors of early death from 526…”
Get full text

Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial by Xie, Mixue, Lu, Ying, Ouyang, Guifang, Li, Xueying, Shi, Ting, Yang, Min, Le, Jing, Hu, Huixian, Zhang, Li, Feng, Weiying, Meng, Haitao, Mai, Wenyuan, Wei, Juying, Qian, Jiejing, Xu, Gaixiang, Yang, Chunmei, Zhou, De, Lin, Yin, Qian, Suying, Kuang, Yuemin, Zhang, Liming, Zhu, Weiguo, Yao, Guoli, Wu, Gongqiang, Hu, Shao, Huang, Xin, Wang, Yungui, Tong, Hongyan, Jin, Jie, Zhu, Hong-Hu

“…To reducing chemotherapy-related toxicity, the chemo-free regimens become a new trend of Ph + ALL treatment. Therefore, we conducted a phase 2 trial of…”
Get full text

New insights into the clinical characteristics of SETD2‐mutated acute myeloid leukaemia by Zhang, Xiang, Wang, Ziwei, Sun, Jiewen, Liu, Lixia, Qin, Jiayue, Huang, Aijie, Yang, Min, Lou, Yinjun, Tang, Gusheng, Mao, Liping, Qian, Jiejin, Wei, Juying, Mai, Wenyuan, Meng, Haitao, Yang, Jianmin, Tong, Hongyan, Wang, Jianmin, Yu, Wenjuan, Ni, Xiong, Jin, Jie

“…Summary As reported, SETD2 is recurrently mutated in acute myeloid leukaemia (AML), but knowledge about the specifics is limited. We enrolled 530 consecutive…”
Get full text

Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score‐matched analysis by Wang, Rong, Zhang, Yi, Chang, Jie, Wang, Huafeng, Lou, Yinjun, Yang, Min, Xu, Gaixiang, Tong, Hongyan, Xie, Wanzhuo, Zhou, De, Wei, Juying, Mai, Wenyuan, Ye, Xiujin, Meng, Haitao, Jin, Jie, Zhu, Hong‐Hu

“…Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy (DAV) has shown safety and efficacy in eligible patients with newly diagnosed acute myeloid…”
Get full text

High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia by Lou, Yinjun, Qian, Wenbin, Meng, Haitao, Mai, Wenyuan, Tong, Hongyan, Tong, Yin, Huang, Jian, Jin, Jie

“…Abstract We conducted a retrospective study to evaluate the efficacy of combining arsenic trioxide (ATO) with all-trans-retinoic acid (ATRA) based induction…”
Get full text

Prognostic factors of patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide-based frontline therapy by Lou, Yinjun, Ma, Yafang, Suo, Shanshan, Ni, Wanmao, Wang, Yungui, Pan, Hanzhang, Tong, Hongyan, Qian, Wenbin, Meng, Haitao, Mai, Wenyuan, Huang, Jian, Yu, Wenjuan, Wei, Juyin, Mao, Liping, Jin, Jie

“…Highlights • We analyzed the prognostic factors of patients with newly diagnosed APL. • FLT3-ITD status and initial WBC count showed no effect on relapse-free…”
Get full text

Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience by Yu, Wenjuan, Mao, Liping, Qian, Jiejing, Qian, Wenbin, Meng, Haitao, Mai, Wenyuan, Tong, Hongyan, Tong, Yin, Jin, Jie

“…To assess the efficacy and toxicity of HAA regimen (Homoharringtonine 4 mg/m 2 /day, days 1–3; cytarabine 150 mg/m 2 /day, days 1–7; aclarubicin 12 mg/m 2…”
Get full text